Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic Disorder

NCT00787111 is registered in ClinicalTrials.gov with Neuropharm as lead sponsor.

NCT NCT00787111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00787111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic Disorder
Lead sponsor
Neuropharm
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2008
Completion date
April 30, 2009
Enrollment
128 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

autistic disorder